Skip to main content
Clinical Trials/NCT04761991
NCT04761991
Recruiting
Not Applicable

Comparison of Cardiovascular Magnetic Resonance and Computed Tomography With Fractional Flow Reserve in the Diagnosis of Suspected Coronary Artery Disease

University of Leicester1 site in 1 country300 target enrollmentNovember 5, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
University of Leicester
Enrollment
300
Locations
1
Primary Endpoint
1. Diagnostic performance of CMR and CT-FFR
Status
Recruiting
Last Updated
10 months ago

Overview

Brief Summary

CONCORD is a prospective observational study evaluating the diagnostic accuracy of cardiovascular magnetic resonance (CMR) and computed tomography with fractional flow reserve (CT-FFR) in patients with suspected coronary artery disease, using invasive fractional flow reserve (FFR) as the reference standard.

Detailed Description

In patients with suspected coronary artery disease (CAD), CT coronary angiography (CTCA) provides excellent sensitivity and negative predictive value, enabling the safe exclusion of significant CAD. However, its positive predictive value remains suboptimal (c.50%). Undertaking additional CT-FFR improves specificity and positive predictive value, reducing unnecessary invasive coronary angiography. It has been established that CMR perfusion imaging offers excellent diagnostic accuracy for the identification of functionally significant coronary artery disease. The diagnostic performance of qualitative CMR perfusion assessment may be further enhanced by additional quantitative assessment. The purpose of this prospective observational study is to evaluate the diagnostic performance of all three modalities (CT-FFR and qualitative and quantitative CMR perfusion imaging), involving 300 patients with suspected coronary artery disease referred for invasive coronary angiography. A subset of 167 subjects will undergo an additional accelerated CMR scan for comparison. Invasively measured fractional flow reserve (FFR) will serve as the reference standard.

Registry
clinicaltrials.gov
Start Date
November 5, 2020
End Date
November 30, 2025
Last Updated
10 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients aged ≥18 years
  • Referred for invasive coronary angiography for investigation of chest pain

Exclusion Criteria

  • Recent acute coronary syndrome (\< 6 months)
  • Previous coronary artery bypass grafting
  • Severe claustrophobia
  • Absolute contraindications to CMR - those with MR conditional or safe devices will be included
  • Second-/third-degree atrioventricular block
  • Severe chronic obstructive pulmonary disease
  • Moderate-severe asthma
  • Estimated glomerular filtration rate \<30 ml/min/1.73m2
  • Women who are pregnant, breast-feeding or of child-bearing potential( premenopausal women)
  • Contraindication to iodinated contrast

Outcomes

Primary Outcomes

1. Diagnostic performance of CMR and CT-FFR

Time Frame: 6 weeks

Diagnostic accuracy of CMR perfusion imaging (quantitative and qualitative analysis) and CT-FFR to determine the presence/absence of significant coronary artery disease at the subject level when compared with invasive FFR.

Secondary Outcomes

  • 2. Diagnostic performance of CMR and CT-FFR(6 weeks)
  • 6. Cost analysis(2 years)
  • 1. Diagnostic performance of CMR and CT-FFR(6 weeks)
  • 3. Diagnostic performance of CMR T1 mapping(6 weeks)
  • 4. Diagnostic performance of hybrid imaging(6 weeks)
  • Diagnostic performance of strain assessment(6 weeks)
  • 7. Clinical endpoints(2 years)
  • 8. Subjective experience(1 day)
  • 9. Time duration of each scan/scan component.(1 day)
  • 10. Image quality(1 day)

Study Sites (1)

Loading locations...

Similar Trials